<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692211</url>
  </required_header>
  <id_info>
    <org_study_id>SHP 08-177</org_study_id>
    <nct_id>NCT00692211</nct_id>
  </id_info>
  <brief_title>Interventions to Improve Colorectal Cancer Screening</brief_title>
  <official_title>Interventions to Improve Colorectal Cancer Screening Rates and Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will evaluate if we can increase colorectal cancer screening rates by directly sending
      screening tests to patients rather than waiting for them to come to clinic visits. We are
      also evaluating a new test--fecal immunochemical tests--which does not require patients to
      make dietary or medication changes. We will see if patients are more likely to complete these
      tests than the standard fecal occult blood tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Colorectal cancer causes a substantial burden of suffering in the elderly VA
      population. Although colorectal cancer screening can reduce both the incidence and mortality
      from colorectal cancer, screening rates are low for the New Mexico VA Health Care System.

      Objectives: We propose to use the electronic medical record and a new technology for fecal
      stool testing to improve screening rates and adherence to screening.

      Methods: The electronic medical record will be used to identify patients who are eligible for
      screening but who do not have an immediately upcoming primary care clinic appointment. We
      will enroll a randomly-selected sample of 800 of these patients who have agreed to
      participate in the study and mail them stool tests along with instructions and educational
      information about the benefits of screening. We will compare the proportion of subjects who
      undergo colorectal cancer screening during the 3-month study period against a
      randomly-selected sample of 400 eligible patients who will require a clinic visit to initiate
      screening. Because adherence for fecal occult blood tests is low, we also propose to evaluate
      a new screening technology--fecal immunochemical stool tests which target intact human
      hemoglobin. These tests can be performed without requiring patients to follow onerous dietary
      and medication restrictions. We will evaluate whether screening adherence (proportion
      completing testing) is higher with fecal immunochemical testing (n = 400) compared to the
      standard fecal occult blood test (n=400). We will also evaluate the yield of advanced
      neoplasia for each of the screening tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colorectal Cancer Screening</measure>
    <time_frame>3 months</time_frame>
    <description>Completing fecal blood test within 90 days of enrolling</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1: Fecal Immunochemical Tests</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mailed fecal immunochemical tests</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Fecal Occult Blood Tests</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mailed fecal occult blood tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mailed fecal occult blood tests</intervention_name>
    <description>Stool blood test</description>
    <arm_group_label>Arm 2: Fecal Occult Blood Tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mailed fecal immunochemical tests</intervention_name>
    <description>Stool blood test</description>
    <arm_group_label>Arm 1: Fecal Immunochemical Tests</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for stool-based colorectal cancer screening, followed in primary care clinic

        Exclusion Criteria:

          -  Need for surveillance or screening colonoscopy

          -  limited life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Mexico VA Health Care System, Albuquerque, NM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Mexico VA Health Care System, Albuquerque, NM</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108-5153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hoffman RM, Steel SR, Yee EF, Massie L, Schrader RM, Moffett ML, Murata GH. A system-based intervention to improve colorectal cancer screening uptake. Am J Manag Care. 2011 Jan;17(1):49-55.</citation>
    <PMID>21348568</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffman RM, Steel S, Yee EF, Massie L, Schrader RM, Murata GH. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med. 2010 May-Jun;50(5-6):297-9. doi: 10.1016/j.ypmed.2010.03.010. Epub 2010 Mar 20.</citation>
    <PMID>20307568</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <results_first_submitted>August 11, 2014</results_first_submitted>
  <results_first_submitted_qc>August 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2014</results_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Fecal Immunochemical Tests</title>
          <description>Mailed fecal immunochemical tests
Fecal immunochemical testing: Stool blood test</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Fecal Occult Blood Tests</title>
          <description>Mailed fecal occult blood tests
Fecal occult blood test: Stool blood test</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Fecal Immunochemical Tests</title>
          <description>Mailed fecal immunochemical tests
Fecal immunochemical testing: Stool blood test</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Fecal Occult Blood Tests</title>
          <description>Mailed fecal occult blood tests
Fecal occult blood test: Stool blood test</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="202"/>
            <count group_id="B3" value="404"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="7.3"/>
                    <measurement group_id="B2" value="63.9" spread="8.1"/>
                    <measurement group_id="B3" value="63.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colorectal Cancer Screening</title>
        <description>Completing fecal blood test within 90 days of enrolling</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Fecal Immunochemical Tests</title>
            <description>Mailed fecal immunochemical tests
Fecal immunochemical testing: Stool blood test</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Fecal Occult Blood Tests</title>
            <description>Mailed fecal occult blood tests
Fecal occult blood test: Stool blood test</description>
          </group>
        </group_list>
        <measure>
          <title>Colorectal Cancer Screening</title>
          <description>Completing fecal blood test within 90 days of enrolling</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study powered to detect 10% difference in proportion of screening adherence based on alpha of 0.05, beta 0.20.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Not adjusted for multiple comparisons, a priori threshold of 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Fecal Immunochemical Tests</title>
          <description>Mailed fecal immunochemical tests
Fecal immunochemical testing: Stool blood test</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Fecal Occult Blood Tests</title>
          <description>Mailed fecal occult blood tests
Fecal occult blood test: Stool blood test</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Hoffman, MD</name_or_title>
      <organization>New Mexico VA Health Care System</organization>
      <phone>505-265-1711 ext 5318</phone>
      <email>richard.hoffman2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

